Lynch Asset Management’s AstraZeneca AZN Stock Holding History

Lynch Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,000	Closed	-$271K	–	48
2022 Q4	$271K	Hold	2,000	–	–	0.23%	44
2022 Q3	$219K	Hold	2,000	–	–	0.2%	51
2022 Q2	$264K	Hold	2,000	–	–	0.22%	52
2022 Q1	$265K	Hold	2,000	–	–	0.19%	50
2021 Q4	$233K	Buy	+2,000	New	+$235K	0.16%	46

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lynch Asset Management's AZN Position: Q1 2023 in Review

Lynch Asset Management sold out of AstraZeneca (AZN) in Q1 2023, closing a stake of 2,000 shares — an estimated $271K sold.

Lynch Asset Management first reported a position in AZN in Q4 2021 and held it in 5 quarters. The position peaked at $271K in Q4 2022. 1,054 funds tracked by Wall St. Rank hold AZN as of Q1 2023.

Lynch Asset Management reported no remaining AstraZeneca position as of Q1 2023 after selling out during the quarter.
Lynch Asset Management sold 2,000 AstraZeneca shares in Q1 2023, an estimated $271K.
Lynch Asset Management first reported a position in AstraZeneca in Q4 2021 and held it in 5 quarters.
Lynch Asset Management's AstraZeneca position peaked at $271K in Q4 2022.
1,054 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2023.

Based on Lynch Asset Management's 13F filing for Q1 2023, filed 20 Apr 2023.